ProCE Banner Activity

Expert Guidance on Monitoring Response to BCR-ABL1 Inhibitors in CML: An Interactive Decision Support Tool

Tool

Use this interactive tool to gain expert guidance on monitoring response to BCR-ABL1 inhibitors in CML, adapting treatment based on response and adverse events, and when to consider treatment-free remission.

Released: January 07, 2025

Expiration: January 06, 2026

Share

Faculty

Daniel J. DeAngelo

Daniel J. DeAngelo, MD, PhD

Professor of Medicine
Harvard Medical School
Chief, Division of Leukemia
Dana-Farber Cancer Institute
Boston, Massachusetts

Michael J. Mauro

Michael J. Mauro, MD

Director, Chronic Myeloid Leukemia Program
Leukemia Service, Department of Medicine
Memorial Sloan Kettering Cancer Center
Professor of Medicine, Weill Cornell Medicine
New York, New York

Neil P. Shah

Neil P. Shah, MD, PhD

Edward S. Ageno Distinguished Professor in Hematology/Oncology
Director, UCSF Molecular Medicine Residency Program
University of California, San Francisco
San Francisco, California

B. Douglas Smith

B. Douglas Smith, MD

Professor, Oncology
Division of Hematologic Malignancies
Sidney Kimmel Comprehensive Cancer Center
Johns Hopkins University School of Medicine
Baltimore, Maryland

Tiffany N. Tanaka

Tiffany N. Tanaka, MD

Associate Professor
Division of Blood & Marrow Transplantation
UC San Diego Moores Cancer Center
La Jolla, California

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from Bristol Myers Squibb and Novartis Pharmaceuticals Corporation.

Bristol Myers Squibb

Novartis Pharmaceuticals Corporation

Disclosure

Primary Author

Daniel J. DeAngelo, MD, PhD

Professor of Medicine
Harvard Medical School
Chief, Division of Leukemia
Dana-Farber Cancer Institute
Boston, Massachusetts

Daniel J. DeAngelo, MD, PhD: consultant/advisor/speaker: Amgen, Autolos, Blueprint, Gilead, Incyte, Jazz, Novartis, Pfizer, Servier, Takeda; researcher (paid to institution): AbbVie, Blueprint, Glycomimetics, Novartis; data and safety monitoring board: Daiichi Sankyo.

Michael J. Mauro, MD

Director, Chronic Myeloid Leukemia Program
Leukemia Service, Department of Medicine
Memorial Sloan Kettering Cancer Center
Professor of Medicine, Weill Cornell Medicine
New York, New York

Michael J. Mauro, MD: consultant/advisor/speaker: Bristol Myers Squibb, Novartis, Pfizer, Takeda, Terns; researcher: Enliven, Novartis, Sun Pharma/Sparc, Terns.

Neil P. Shah, MD, PhD

Edward S. Ageno Distinguished Professor in Hematology/Oncology
Director, UCSF Molecular Medicine Residency Program
University of California, San Francisco
San Francisco, California

Neil P. Shah, MD, PhD: research: Bristol Myers Squibb Oncology; other financial or material support: Novartis Oncology.

B. Douglas Smith, MD

Professor, Oncology
Division of Hematologic Malignancies
Sidney Kimmel Comprehensive Cancer Center
Johns Hopkins University School of Medicine
Baltimore, Maryland

B. Douglas Smith, MD: consultant/advisor/speaker: Bristol Myers Squibb, Novartis, Servier.

Tiffany N. Tanaka, MD

Associate Professor
Division of Blood & Marrow Transplantation
UC San Diego Moores Cancer Center
La Jolla, California

Tiffany N. Tanaka, MD: consultant/advisor/speaker: Bristol Myers Squibb, Gilead, Rigel, Servier.